Biofrontera Inc. (NASDAQ:BFRI – Get Rating) fell 1.1% on Monday . The stock traded as low as $0.91 and last traded at $0.93. 3,094 shares were traded during mid-day trading, a decline of 100% from the average session volume of 1,218,819 shares. The stock had previously closed at $0.94.
Biofrontera Stock Performance
The stock has a fifty day moving average price of $1.01 and a 200-day moving average price of $1.29. The firm has a market cap of $24.83 million, a PE ratio of -0.82 and a beta of 1.12.
Get
Biofrontera alerts:
Biofrontera (NASDAQ:BFRI – Get Rating) last announced its quarterly earnings results on Monday, November 14th. The company reported ($0.23) earnings per share for the quarter, beating analysts' consensus estimates of ($0.32) by $0.09. Biofrontera had a negative net margin of 44.62% and a negative return on equity of 113.65%. The firm had revenue of $4.32 million for the quarter, compared to analysts' expectations of $4.32 million. As a group, equities analysts predict that Biofrontera Inc. will post -0.92 earnings per share for the current fiscal year.
Institutional Trading of Biofrontera
Several large investors have recently added to or reduced their stakes in BFRI. State Street Corp lifted its stake in shares of Biofrontera by 55.8% during the second quarter. State Street Corp now owns 22,900 shares of the company's stock worth $43,000 after purchasing an additional 8,200 shares in the last quarter. Bard Associates Inc. lifted its position in Biofrontera by 5.4% during the 2nd quarter. Bard Associates Inc. now owns 259,275 shares of the company's stock worth $482,000 after acquiring an additional 13,200 shares in the last quarter. XTX Topco Ltd purchased a new position in Biofrontera in the 1st quarter worth approximately $48,000. Northern Trust Corp acquired a new stake in Biofrontera in the second quarter valued at approximately $39,000. Finally, BlackRock Inc. grew its position in Biofrontera by 894.0% in the first quarter. BlackRock Inc. now owns 100,505 shares of the company's stock valued at $335,000 after acquiring an additional 90,394 shares in the last quarter. 6.84% of the stock is currently owned by institutional investors and hedge funds.
Biofrontera Company Profile
(Get Rating)
Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp.
Read More
- Get a free copy of the StockNews.com research report on Biofrontera (BFRI)
- Three Healthcare Penny Stocks to Watch In The New Year
- Southwest Airlines Stock, There is a Lot to Love
- MarketBeat: Week in Review 12/19 – 12/23
- These Steelmakers Deserve A Place On Your 2023 Watch List
- Inflation Cools, Where Does The S&P 500 Go Now
Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.
